Palbociclib-Induced Pneumonitis: A Reported Case and Review of the Literature
The treatment of metastatic breast cancer has undergone significant changes in recent years. Palbociclib, a selective cyclin-dependent kinase 4/6 (CDK4/6) inhibitor, has become a cornerstone in the treatment of hormone receptor-positive, HER2-negative advanced breast cancer, in addition to endocrine therapy. While palbociclib is generally well-tolerated, pneumonitis has emerged as a rare but serious adverse effect. This article presents a case of palbociclib-induced pneumonitis leading to death, followed by a comprehensive review of the literature to outline the clinical features, diagnosis, and management strategies for this condition.
Authors
- Rhizlane Belbaraka (ORCID: https://orcid.org/0000-0002-3947-775X)
- Othmane Zouiten (ORCID: https://orcid.org/0009-0007-5327-2797)
- Leila Afani (ORCID: https://orcid.org/0000-0002-0816-8057)
- Ismail Essaadi
- Fatim-Zahra Megzar
- Mohamed El Fadli
- Taji Raja
Institutions
- Centre Hospitalier Universitaire Mohammed VI (MA)
Publication Details
- Journal
- Scholars Journal of Medical Case Reports
- Published
- 2026-11-13
- DOI
- https://doi.org/10.36347/sjmcr.2026.v14i11.047
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 0.00